Burgdorf, 09.11.2017, 7.00 a.m. – During the first six months of the business year 2017/18, Ypsomed generated a consolidated total turnover of CHF 213.4 million. The growth corresponds to an increase in turnover of 15.1% (previous year: CHF 185.4 million). The net profit for the reporting period amounts to CHF 23.4 million (previous year CHF 22.4 million). The operating result amounts to CHF 26.9 million with an EBIT margin of 12.9 %. Ypsomed expects a growth in turnover of approximately 18% versus the presently forecast 15% and increases the forecast to an operating result of around CHF 60 million for the business year 2017/18.
Burgdorf, 24.10.2017, 7.00 a.m. – Ypsomed and the US Bigfoot Biomedical company today announced their agreement for a partnership. Ypsomed will supply Bigfoot Biomedical with a modified, patented version of the Orbit infusion set. This will be used by Bigfoot in their clinical study on automated insulin therapy in people with diabetes.
Burgdorf, 10.10.2017, 7.00 am – Following the successful launch of its own insulin pump, the mylife YpsoPump, Ypsomed pursues its continued growth and invests in establishing new subsidiaries throughout Europe. At the same time, the mylife YpsoPump is being launched in further European countries.
Burgdorf, 27th September 2017, 7.00 a.m. – On 26th September 2017, groundbreaking took place for Ypsomed’s new production facility in the Industrial Park of Schwerin, Germany. Ypsomed is to invest over EUR 100 million in the new production site. Production will commence during the first half of 2019. Ypsomed plans to create roughly 150 jobs in the region over the next five years.
Burgdorf, 21 July 2017, 7 a.m. – Ypsomed has been the exclusive distributor for the mylife™ OmniPod® patch pump outside the USA since 2010. During this period, Ypsomed established therapy with the innovative insulin pump in Europe, gaining market shares of up to 20% in part. The distribution agreement with Insulet Corp. will end as per 30 June 2018. The parties could not agree on extending the contract as the price demanded by Insulet Corp. would have made continued economic viability impossible. Ypsomed is well set for the future and will introduce its own tubeless mylife™ YpsoPod® insulin pump in the mid-term.
Burgdorf, 24 May 2017, 7.00 a.m. – In the financial year 2016/17, the Ypsomed Group generated consolidated sales of CHF 389.6 million (previous year: CHF 336.9 million). Compared with the previous year, this represents an increase in sales of 15.6%. The operating results (EBIT) also increased by 24.4% compared to the previous year, from CHF 44.4 million to CHF 55.3 million. Profitability at the EBIT level has now risen to 14.2% (previous year: 13.2%). Compared with the previous year, the net profits were raised by 29.1% from CHF 35.8 million to CHF 46.2 million. Some demanding tasks lie ahead for the coming financial year, but Ypsomed remains confident and again expects a growth in sales of approximately 15% for the financial year 2017/18.
Burgdorf, 12 April 2017, 7.00 a.m. – Ypsomed has collaborated with Biocon, an emerging global biopharmaceutical company headquartered in India, to customise its reusable YpsoPen for use with Biocon’s insulin cartridges. This customised reusable pen will be marketed by Biocon as INSUPen Pro™ in Malaysia.
Burgdorf, 25 January 2017, 7.00 a.m. – Following 18 months of industrialisation, Ypsomed opened its new production line in their Solothurn works and will have created over 50 new jobs on final expansion. The inauguration was held yesterday with representatives of local commerce and guests from politics in attendance.
Burgdorf, 12 January 2017, 7.00 a.m. – On 11 January 2017, Ypsomed was honoured with the 20th Solothurn Business Award. Ypsomed received an award for their outstanding business performance in the canton of Solothurn in terms of implementing modern work models and for its commitment to promoting the production location in Switzerland. The ceremony was held in front of over 350 attendees representing commerce, politics and administration.